Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28240301 | 1.00 | CA1 (0.49) | CA1CA2CYP2D6HDAC8HDAC6 | |
| SCHEMBL8258147 | 0.92 | CA2 (0.61) | CA1CA2CYP2D6CTSKBIRC2 | |
| SCHEMBL27817674 | 0.83 | CA1 (0.52) | CA1CA2HDAC8HDAC6HDAC7 | |
| SCHEMBL4835503 | 0.83 | FOLH1 (0.39) | CA1CA2CYP2D6HDAC8HDAC6 | |
| SCHEMBL8237941 | 0.83 | CA1 (0.50) | CA1CA2HDAC8HDAC6HDAC7 | |
| SCHEMBL629052 | 0.83 | CYP2D6 (0.38) | CA1CA2CYP2D6HDAC8HDAC6 | |
| SCHEMBL16798232 | 0.82 | HDAC1 (0.54) | CA2CYP2D6HDAC8HDAC6HDAC7 | |
| SCHEMBL7051239 | 0.82 | HDAC1 (0.54) | CA2CYP2D6HDAC8HDAC6HDAC7 | |
| SCHEMBL6448846 | 0.82 | HDAC1 (0.54) | CA2CYP2D6HDAC8HDAC6HDAC7 | |
| SCHEMBL16310556 | 0.82 | HDAC8 (0.39) | CA1CA2CYP2D6HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110358752-B | Aspergillus oryzae lipase and application thereof in preparation of brivaracetam chiral intermediate | 浙江工业大学 | 2021-05-11 | — | — | CN | claimed |
| CN-110358752-A | A kind of Aspergillus oryzae lipase and preparing the application in Bu Waxitan chiral intermediate | 浙江工业大学 | 2019-10-22 | — | — | CN | claimed |
| US-20230242481-A1 | Preparation Method For Brivaracetam | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| CN-110036001-B | Benzo [ b ] thiophene compounds as STING agonists | 默沙东公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-111675643-B | Preparation method of brivaracetam | 浙江天宇药业股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-110358752-B | Aspergillus oryzae lipase and application thereof in preparation of brivaracetam chiral intermediate | 浙江工业大学 | 2021-05-11 | — | — | CN | disclosed |
| CN-110358752-B | Aspergillus oryzae lipase and application thereof in preparation of brivaracetam chiral intermediate | 浙江工业大学 | 2021-05-11 | — | — | CN | disclosed |
| CN-111675643-A | Preparation method of brivaracetam | 浙江天宇药业股份有限公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111170881-A | Preparation method of brivaracetam intermediate | 上海医药集团股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-108689903-B | Novel preparation method of brivaracetam | 北京艾百诺医药股份有限公司 | 2019-12-24 | — | — | CN | disclosed |
| CN-108503573-B | A kind of new preparation method of Bu Waxitan | 北京艾百诺医药股份有限公司 | 2019-11-22 | — | — | CN | disclosed |
| CN-110358752-A | A kind of Aspergillus oryzae lipase and preparing the application in Bu Waxitan chiral intermediate | 浙江工业大学 | 2019-10-22 | — | — | CN | disclosed |
| CN-110358752-A | A kind of Aspergillus oryzae lipase and preparing the application in Bu Waxitan chiral intermediate | 浙江工业大学 | 2019-10-22 | — | — | CN | disclosed |
| CN-108689903-A | A kind of new preparation method of Bu Waxitan | 北京艾百诺医药股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-108503573-A | A kind of new preparation method of Bu Waxitan | 北京艾百诺医药股份有限公司 | 2018-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242481-A1 | Preparation Method For Brivaracetam | BLVRB, BPGM, CYP2B6 | CA1 4490/4885CA2 1939/4885CYP2D6 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.